Warren Raye

Warren Raye

Auto-generated profile, based on publicly available information

Warren Raye

Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 January 2010 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
MBMichael Buchert
Michael Buchert
MPMarina Papin
Marina Papin
CBCaroline Bonnans
Caroline Bonnans
Charbel DaridoCharbel Darido
Charbel Darido
WRWarren S. Raye
Warren S. Raye
FHFrédéric Hollande
Frédéric Hollande
Symplekin is a ubiquitously expressed protein involved in cytoplasmic RNA polyadenylation and transcriptional regulation and is localized at tight junctions (TJs) in epithelial cells. Nuclear symplekin cooperates with the Y-box transcription factor zonula occludens 1-associated nucleic acid-binding protein (ZONAB) to increase the transcription of cell cycle-related genes and also inhibits differentiation of intestinal cells. We detected high levels of nuclear symplekin in 8 of 12 human colorectal cancer (CRC) samples. shRNA-mediated reduction of symplekin expression was sufficient to decrease significantly the anchorage-independent growth and proliferation of HT-29 CRC cells as well as their tumorigenicity when injected into immunodeficient animals. Symplekin down-regulation also was found to alter ion transport through TJs, to promote the localization of ZONAB in the membrane rather than the nucleus, and strongly to enhance cell polarization in a 3D matrix, leading to the formation of spheroids organized around a central lumen. Claudin-2 expression was reduced following symplekin down-regulation, an effect mimicked when ZONAB expression was down-regulated using selective siRNA. Virus-mediated restoration of claudin-2 expression was found to restore nuclear expression of ZONAB in HT29ΔSym cells and to rescue the phenotypic alterations induced by symplekin down-regulation of cell polarity, paracellular transport, ZONAB localization, cyclin D1 expression, proliferation, and anchorage-independent growth. Finally, siRNA-mediated claudin-2 down-regulation increased the transepithelial resistance and decreased cyclin D1 expression and ZONAB nuclear localization, similar to observations in symplekin-depleted cells. Our results suggest that nuclear overexpression of symplekin promotes tumorigenesis in the human colon and that the regulation of claudin-2 expression is instrumental in this effect.

10 April 2007 in European Journal of Neuroscience
Verified
Journal Article
Closed access
PDF file
WRWarren S. Raye
Warren S. Raye
NTNathalie Tochon‐Danguy
Nathalie Tochon‐Danguy
CPColin Pouton
Colin Pouton
JHJohn M. Haynes
John M. Haynes

1 May 2005 in Australian Veterinary Journal
Verified
Journal Article
Closed access
PDF file
WRW. Raye
W. Raye
JMJ. Muhling
J. Muhling
LWL. Warfe
L. Warfe
JBJr Buddle
Jr Buddle
CPC. Palmer
C. Palmer
GWGe Wilcox
Ge Wilcox

10 November 2007 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
BKBorut Klopcic
Borut Klopcic
AAAmber Appelbee
Amber Appelbee
WRWarren Raye
Warren Raye
FLFrances Lloyd
Frances Lloyd
JJJames C. I. Jooste
James C. I. Jooste
ILIan Craig Lawrance
Ian Craig Lawrance

1 June 2009 in Cytokine
Verified
Journal Article
Closed access
AUAradhana Upadhyay
Aradhana Upadhyay
GSGaurav Sharma
Gaurav Sharma
SKSatu Kivivuori
Satu Kivivuori
WRWarren S. Raye
Warren S. Raye
EZEbrahim Zabihi
Ebrahim Zabihi
JJJalal A. Jazayeri
Jalal A. Jazayeri

1 April 2007 in Journal of Interferon & Cytokine Research
Verified
Journal Article
Closed access
JJJalal A. Jazayeri
Jalal A. Jazayeri
NWNicole De Weerd
Nicole De Weerd
WRWarren Raye
Warren Raye
SKSatu Kivivuori
Satu Kivivuori
EZEbrahim Zabihi
Ebrahim Zabihi
GCGraeme J. Carroll
Graeme J. Carroll
Leukemia inhibitory factor (LIF) and oncostatin M (OSM) are found in appreciable concentrations in synovial fluid from patients with rheumatoid arthritis (RA) but not osteoarthritis. Accordingly, both are potential therapeutic targets in inflammatory diseases of the joints. Several LIF antagonists have been developed. They have the capacity to inhibit the biologic activities of not only LIF but also other interleukin-6 (IL-6) subfamily cytokines, including OSM. Both LIF and OSM share the same receptor, which is part of a cytokine receptor super family in which the glycoprotein 130 (gp130) subunit is a common constituent. The aim of this study was to evaluate the antagonistic potentials of two LIF mutants, LIF05 and MH35-BD. Both are mutant forms of human LIF with reduced affinity for gp130 and greater LIF receptor (LIFR) binding affinity. The results, using Ba/F3 cell proliferation assay, acute-phase protein (haptoglobin) induction analysis in HepG2 human hepatoma cells, a porcine cartilage glycosaminoglycan release assessment for proteoglycan degradation, and a collagen release assay, show that these antagonists inhibit relevant LIF, OSM, and other IL-6 subfamily cytokines in vitro albeit with differential potencies and have, therefore, therapeutic potential for treatment of RA and perhaps other diseases.